Home › Drievoudig negatieve borstkanker › Pennsylvania › Pittsburgh
Drievoudig negatieve borstkanker klinische studies in Pittsburgh, PA
11 studies voor Drievoudig negatieve borstkanker zoeken deelnemers op locaties in en rond Pittsburgh (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Rekruteren
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruterenFase 1
- UPMC, Pittsburgh
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekruterenFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruterenFase 3
- UPMC Magee-Womens Hospital, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruterenFase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Research Site, Pittsburgh
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruterenFase 2/3
- Local Institution - 0360, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- Allegheny Health Network, Pittsburgh
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
RekruterenObservatieonderzoek
- UPMC Hillman Cancer, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RekruterenFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Drievoudig negatieve borstkanker studies in andere steden
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Andere studies in Pittsburgh
- Niet-kleincellige longkanker48 studies
- Kanker (alle vormen)41 studies
- Borstkanker39 studies
- Colorectale kanker32 studies
- Metastatische kanker31 studies
- Melanoom31 studies
- Eierstokkanker30 studies
- Endometriumkanker23 studies
- Prostaatkanker23 studies
- Longkanker23 studies
- Plaveiselcelcarcinoom van hoofd en hals22 studies
- Beroerte22 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.